摘要
目的报道并分析1例以骨破坏为首发表现的费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL),采用伊马替尼为基础个体化方案的诊断和治疗。方法采用病例报告及文献复习的方式对以骨破坏起病的ALL患者及Ph+ALL治疗进展进行描述。结果患者诊断Ph+ALL明确,经伊马替尼为基础治疗获得诱导缓解,维持分子学缓解17个月。结论对以骨破坏为首发表现者,应考虑ALL诊断可能;伊马替尼为基础的标准化疗方案有可能改善Ph+ALL的治疗模式和预后。
Objective To report and analyze one case of Philadelphia chromosome-positive （Ph^＋） acute lymphoblastic leukemia （ALL） initially presented with skeletal destruction treated with imatinib-based personal therapy. Methods We described the therapeutic advancements for ALL cases initially presented as skeletal destruction and Ph^＋ ALL through case report and literature review, Results Definite diagnosis of Ph^＋ ALL was made for the patient who subsequently obtained inductive remission and 17-month molecular remission with the aid of imatinib-based regimen. Conclusions We should take potential diagnosis of ALL into consideration for patients with skeletal destruction. Imatinib-based standard chemotherapeutic regimen may improve therapeutic model and prognosis of Ph^＋ ALL.
出处
《华西医学》
CAS
2014年第4期620-623,共4页
West China Medical Journal
基金
国家自然科学基金青年基金(0040205401996)
卫生部卫生行业科研专项(201202017)~~
